Intuitive Surgical - ISRG Stock Forecast, Price & News

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of research reports. BTIG Research decreased their price target on shares of Intuitive Surgical from $355.00 to $247.00 and set a "buy" rating for the company in a research note on Monday, July 18th. Morgan Stanley decreased their price target on shares of Intuitive Surgical from $300.00 to $225.00 and set an "equal weight" rating for the company in a research note on Friday, July 15th. Stifel Nicolaus decreased their target price on shares of Intuitive Surgical from $325.00 to $270.00 in a research note on Monday, July 18th. Evercore ISI decreased their target price on shares of Intuitive Surgical from $210.00 to $175.00 in a research note on Friday, July 22nd. Finally, TheStreet downgraded shares of Intuitive Surgical from a "b-" rating to a "c+" rating in a research note on Thursday, May 19th. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $273.23.

Intuitive Surgical Stock Down 0.4 %

ISRG traded down $0.93 during trading on Monday, hitting $237.44. The company's stock had a trading volume of 16,460 shares, compared to its average volume of 2,125,801. Intuitive Surgical has a one year low of $186.83 and a one year high of $369.69. The firm has a market cap of $84.79 billion, a PE ratio of 60.65, a P/E/G ratio of 6.64 and a beta of 1.29. The business's 50 day simple moving average is $213.87 and its 200-day simple moving average is $248.20.

Intuitive Surgical (NASDAQ:ISRG - Get Rating) last announced its quarterly earnings data on Thursday, July 21st. The medical equipment provider reported $1.14 EPS for the quarter, beating the consensus estimate of $1.01 by $0.13. Intuitive Surgical had a net margin of 24.05% and a return on equity of 12.04%. During the same quarter in the prior year, the business posted $1.42 EPS. Equities research analysts expect that Intuitive Surgical will post 3.76 EPS for the current fiscal year.

Insider Activity

In other Intuitive Surgical news, Director Amal M. Johnson sold 6,375 shares of Intuitive Surgical stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $238.04, for a total value of $1,517,505.00. Following the completion of the transaction, the director now directly owns 11,224 shares of the company's stock, valued at approximately $2,671,760.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Intuitive Surgical news, Director Amal M. Johnson sold 6,375 shares of the business's stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $238.04, for a total value of $1,517,505.00. Following the completion of the sale, the director now directly owns 11,224 shares of the company's stock, valued at approximately $2,671,760.96. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Gary S. Guthart sold 79,412 shares of the business's stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $216.30, for a total transaction of $17,176,815.60. Following the completion of the sale, the chief executive officer now directly owns 54,607 shares of the company's stock, valued at $11,811,494.10. The disclosure for this sale can be found here. Insiders have sold 94,787 shares of company stock worth $20,719,321 in the last three months. Company insiders own 0.90% of the company's stock.